A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon
  • Indications Hypoglycaemia; Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Zealand Pharma

    • Most Recent Events

    • 20 Mar 2018 According to a Zealand Pharma media release, the full results will be published at an appropriate scientific conference.
    • 20 Mar 2018 According to a Zealand Pharma media release, the first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary and key secondary objectives.
    • 21 Feb 2018 According to a Zealand Pharma media release, results from this first phase 3 trial of dasiglucagon for the treatment of severe hypoglycemia are expected by mid-Q2 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top